HEIDELBERG PHARMA AG

Heidelberg Pharma AG’s 2026 AGM saw 98.7% approval and a new oncology‑savvy board, boosting confidence in its ADC pipeline and future growth prospects.

Heidelberg Pharma AG’s cancer‑therapy focus faces a tough test: falling stock, negative P/E, and strategic questions that threaten its biopharma future.

Heidelberg Pharma’s ADC platform HDP‑103 shows promising pre‑clinical results against PSMA‑positive metastatic prostate cancer, positioning the company for a new oncology focus.

Heidelberg Pharma AG unveils promising pre‑clinical data for its PSMA‑targeting, amanitin‑based ADC HDP‑103, showing potent tumor inhibition in models of metastatic castration‑resistant prostate cancer, poised for AACR 2026.

Heidelberg Pharma’s $20 million deal with Soleus Capital and HealthCare Royalty could accelerate its oncology pipeline or expose financial risk—what investors should watch.

Heidelberg Pharma AG, a German biopharma leader, focuses on innovative cancer therapies and recent milestone payments from Takeda, driving future growth in oncology.

Heidelberg Pharma AG receives milestone payment from Takeda, boosting its Amanitin‑based ADC research and supporting future cancer therapy development.

Heidelberg Pharma AG has revised its financial guidance for 2025, citing recent strategic realignments and cost-saving initiatives as the reason for a downward adjustment in projected revenue and other financial metrics.

Heidelberg Pharma AG is a leading biopharmaceutical company dedicated to advancing cancer therapies and inflammatory disease treatments through innovative research and development in pharmacology and molecular biology.

Heidelberg Pharma AG, a German biopharmaceutical company, faces challenges in its financial performance and strategic decisions as it navigates the complex landscape of biotechnology and cancer therapies.